The Use of Serum Zinc to Prostate-Specific Antigen Ratio As A Biomarker in the Prediction of Prostate Biopsy Outcomes

References

• Polascik TJ , OesterlingJE, PartinAW. Prostate spesific antigen: a decade of discovery – what we have learned and where we are going. J. Urol.162, 293–306 (1999).
   PubMed Web of Science ®Google Scholar
• Prensner JR , RubinMA, WeiJT, ChinnaiyanAM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med.4 (127), 127rv3 (2012).
   PubMed Web of Science ®Google Scholar
• Kelleher SL , McCormickNH, VelasquezV, LopezV. Zinc in specialized secretory tissues: roles in the pancreas, prostate, and mammary gland. Adv. Nutr.2, 101–111 (2011).
   PubMed Web of Science ®Google Scholar
• Ogunlewe JO , OsegbeDN. Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer.63, 1388–1392 (1989).
   PubMed Web of Science ®Google Scholar
• Feustel A , WennrichR, DittrichH. Zinc, cadmium and selenium concentrations in separated epithelium and stroma from prostatic tissues of different histology. Urol. Res.15, 161–163 (1987).
   PubMedGoogle Scholar
• Brys M , NawrockaAD, MiekosEet al. Zinc and cadmium analysis in human prostate neoplasms. Biol. Trace Elem. Res.59, 145–152 (1997).
   PubMed Web of Science ®Google Scholar
• Whelan P , WalkerBE, KelleherJ. Zinc, vitamin A and prostatic cancer. Br. J. Urol.55, 525–528 (1983).
   PubMedGoogle Scholar
• Goel T , SankhwarSN. Comparative study of Zn levels in benign and malignant lesions of prostate. Scand. J. Urol. Nephrol.40, 108–112 (2006).
   PubMed Web of Science ®Google Scholar
• Tiwari VS , AgrawalA, MohdS, AgrawalV. Comparative study of zinc levels in benign and malignant lesions of prostate. Indian J. Surg.66, 352–355 (2004).
   Google Scholar
• Li XM , ZhangL, LiJet al. Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/ml and 10 ng/ml. Asian J. Androl.7, 323–328 (2005).
   PubMed Web of Science ®Google Scholar
• Ploussard G , EpsteinJI, MontironiRet al. The contemporary concept of significant versus insignificant prostate cancer. Eur. Urol.60, 291–303 (2011).
   PubMed Web of Science ®Google Scholar
• Cotter K , KonetyB, OrdonezMA. Contemporary management of prostate cancer. F1000Res.5, doi:10.12688/f1000research.7183.1 (2016).
   Google Scholar
• Patel KM , GnanapragasamVJ. Novel concepts for risk stratification in prostate cancer. J. Clin. Urol.9, 18–23 (2016).
   PubMedGoogle Scholar
• Ruopp MD , PerkinsNJ, WhitcombBWet al. Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom. J.50, 419–430 (2008).
   PubMed Web of Science ®Google Scholar
• Vickers AJ , ElkinEB. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making26, 565–574 (2006).
   PubMed Web of Science ®Google Scholar
• Bruzzese D , MazzarellaC, FerroMet al. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with ‘gray’ prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Transl. Res.164, 444–451 (2014).
   PubMed Web of Science ®Google Scholar
• Filella X , GimenezN. Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin. Chem. Lab. Med.51, 729–739 (2013).
   PubMed Web of Science ®Google Scholar
• Gaudreau PO , StaggJ, SoulièresD, SaadF. The present and future of biomarkers in prostate cancer: proteomics, genomics and immunology advancements. Biomark. Cancer8 (Suppl. 2), 15–33 (2016).
   PubMedGoogle Scholar
• Mohammed AA . Biomarkers in prostate cancer: new era and prospective. Med. Oncol.31, 140 (2014).
   PubMed Web of Science ®Google Scholar
• Benchikh EFA , VillersA. Molecular forms of PSA. Prog. Urol.17, 165–171 (2007).
   PubMed Web of Science ®Google Scholar
• de Cobelli O , TerraccianoD, TagliabueEet al. Predicting pathological features at radical prostatectomy in patients with prostate cancer eligible for active surveillance by multiparametric magnetic resonance imaging. PLoS ONE10 (10), e0139696 (2015).
   PubMed Web of Science ®Google Scholar
• Habib FK , DembinskiTC, StitchSR. The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin. Chim. Acta104, 329–335 (1980).
   PubMed Web of Science ®Google Scholar
• Feustel A , WennrichR. Zinc and cadmium plasma and erythrocyte levels in prostatic carcinoma, BPH, urological malignancies and inflammations. Prostate8, 75–79 (1986).
   PubMed Web of Science ®Google Scholar
• Park SY , WilkensLR, MorrisJS, HendersonBE, KolonelLN. Serum zinc and prostate cancer risk in a nested case–control study: the multiethnic cohort. Prostate73, 261–266 (2013).
   PubMed Web of Science ®Google Scholar
• de Cobelli O , TerraccianoD, TagliabueEet al. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol. Oncol.33, 201 (2015).
   Google Scholar
• Ferro M , LucarelliG, BruzzeseDet al. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget8, 18424–18434 (2017).
   PubMedGoogle Scholar
• Vukotic V , CerovicS, KozomaraM, LazicM. The predictive value of PSA in diagnosis of prostate cancer in non screened population. Acta Chir. Lugosl.52, 81–7 (2005).
   PubMedGoogle Scholar
• Catalona WJ , PartinAW, SlawinKMet al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA279, 1542–1547 (1998).
   PubMed Web of Science ®Google Scholar